首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1447809

全球静脉注射免疫球蛋白市场规模、份额、成长分析、按应用（低丙种球蛋白血症、CIDP）、按类型（IgG、IgM）、按配销通路（医院药房、专业药房）-2024-2031 年产业预测

Global Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP), By Type(IgG, IgM), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy) - Industry Forecast 2024-2031

出版日期: 2024年02月27日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球静脉免疫球蛋白市场规模为119.8亿美元，预计将从2023年的128.5亿美元成长到2031年的225.9亿美元，在预测期内（2024-2031年）复合CAGR为7.3%。

全球静脉注射免疫球蛋白 (IVIG) 市场受到一些主要因素的推动，例如老年人口的增长、免疫缺陷疾病的增加、IVIG 治疗的标籤外适应症的使用增加以及 IVIG 疗法的日益采用。越来越多的免疫系统缺陷患者仍然是 IVIG 供应的创造和需求背后的关键力量。越来越多的患者面临出血问题和慢性发炎性脱髓鞘多发性神经病变（CIDP），导致这个全球市场的快速成长。由于医疗保健行业投资增加，IVIG 市场正在成长。此外，自体免疫疾病和其他病理状况的日益普及是 IVIG 产品市场不断增长的一个主要因素，凸显了它们在满足一系列医疗需求方面的关键作用。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Grifols SA
Octapharma AG
ADMA Biologics
LFB Biotechnologies
Kedrion Biopharma,
Intas Pharmaceuticals.
Biotest AG
BDI Pharma Inc.
Shanghai RAAS Blood Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
CSL Behring
Baxter International Inc.
China Biologics Products Inc.

简介目录

Product Code: SQMIG35A2611

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.85 billion in 2023 to USD 22.59 billion by 2031, growing at a CAGR of 7.3% during the forecast period (2024-2031).

The Global Intravenous Immunoglobulin (IVIG) Market is being driven by some major factors like the growing elderly population, an increase in immunodeficiency disorders, the increased usage of off-label indications for IVIG treatments, and the increasing adoption of IVIG therapies. The increasing number of individuals with immune system deficiencies continues to be the key force behind the creation and need for IVIG supplies. The increasing number of patients dealing with bleeding problems and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is leading to the rapid growth of this global market. The IVIG market is growing as a result of the increased investments made in the healthcare industry. Furthermore, the increasing prevalence of autoimmune diseases and other pathological conditions is a major factor in the growing market for IVIG products, highlighting their critical role in meeting a range of medical needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Intravenous Immunoglobulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Intravenous Immunoglobulin Market Segmental Analysis

Four segments make up the worldwide intravenous immunoglobulin market: those based on application, type, distribution channel, and region. The market is divided into several segments based on the application, including Hypogammaglobulinemia, Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Guillain-Barre Syndrome, Kawasaki Disease, and Others. The market is divided into IgG, IgM, IgA, IgE, and IgD segments based on type. The market is divided into Hospital Pharmacy, Specialty Pharmacy, and others segments based on the distribution channel. The market is divided into three regions: North America, Asia Pacific, and Latin America.

Drivers of the Global Intravenous Immunoglobulin Market

One of the main factors driving the growth of the intravenous immunoglobulin market is the widespread adoption of IVIG as the primary treatment option for a variety of uncommon immunological and neurological disorders, most notably primary immunodeficiency (PI) and related diseases. IVIG therapy's widespread adoption as the primary treatment for these illnesses attests to its relevance and effectiveness in controlling them.

Restraints in the Global Intravenous Immunoglobulin Market

Demyelinating illnesses come with a significant financial burden due to diagnosis and treatment costs. One prominent factor impeding the market's growth is the increasing expenses associated with IVIG treatment. IVIG infusions are recurrent, usually given every 3-4 weeks; there are roughly 12-16 sessions per year. IVIG is expected to cost USD 73.89 per gram, for a total anticipated cost of approximately USD 10,000.

Market Trends of the Global Intravenous Immunoglobulin Market

A number of significant trends are influencing the market's evolution and redefining its growth and advancement trajectory. Among them, the most notable trend in the treatment of neurological illnesses is the increasing use of intravenous immunoglobulin (IVIG), which underscores the drug's expanding use outside its conventional applications. Furthermore, a significant change in IVIG therapy is the application of personalized medicine concepts, which allow for the customization of treatments to meet the specific needs of each patient. The development of new immunomodulatory therapies is also reshaping the field and opening up new therapeutic options.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Intravenous Immunoglobulin Market by Application

Market Overview
Hypogammaglobulinemia
CIDP
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-Barre Syndrome
and Others

Global Intravenous Immunoglobulin Market by Type

Market Overview
IgG
IgM
IgA
IgE
and IgD

Global Intravenous Immunoglobulin Market by Distribution Channel

Market Overview
Hospital Pharmacy
Specialty Pharmacy
and Others

Global Intravenous Immunoglobulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma,
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BDI Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologics Products Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments